Plague vaccines: current developments and future perspectives

VA Feodorova, VL Motin - Emerging microbes & infections, 2012 - Taylor & Francis
Despite many decades of intensive studies of Yersinia pestis, the causative agent of plague,
there is no safe and efficient vaccine against this devastating disease. A recently developed …

Protecting against plague: towards a next-generation vaccine

ED Williamson, PCF Oyston - Clinical & Experimental …, 2013 - academic.oup.com
The causative organism of plague is the bacterium Yersinia pestis. Advances in
understanding the complex pathogenesis of plague infection have led to the identification of …

Mutated and Bacteriophage T4 Nanoparticle Arrayed F1-V Immunogens from Yersinia pestis as Next Generation Plague Vaccines

P Tao, M Mahalingam, ML Kirtley, CJ van Lier… - PLoS …, 2013 - journals.plos.org
Pneumonic plague is a highly virulent infectious disease with 100% mortality rate, and its
causative organism Yersinia pestis poses a serious threat for deliberate use as a bioterror …

IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection

JS Lin, LW Kummer, FM Szaba… - The Journal of …, 2011 - journals.aai.org
Pneumonic plague is one of the world's most deadly infectious diseases. The causative
bacterium, Yersinia pestis, has the potential to be exploited as a biological weapon, and no …

Protection Elicited by Attenuated Live Yersinia pestis Vaccine Strains against Lethal Infection with Virulent Y. pestis

CK Cote, SS Biryukov, CP Klimko, JL Shoe, M Hunter… - Vaccines, 2021 - mdpi.com
The etiologic agent of plague, Yersinia pestis, is a globally distributed pathogen which
poses both a natural and adversarial threat. Due largely to the rapid course and high …

Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague

DA Wagner, SM Kelly, AC Petersen, N Peroutka-Bigus… - Acta biomaterialia, 2019 - Elsevier
Yersinia pestis, the causative agent of pneumonic plague, induces a highly lethal infection if
left untreated. Currently, there is no FDA-approved vaccine against this pathogen; however …

A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model

KA Gregg, E Harberts, FM Gardner, MR Pelletier… - Vaccine, 2018 - Elsevier
Vaccination can significantly reduce worldwide morbidity and mortality to infectious
diseases, thereby reducing the health burden as a result of microbial infections. Effective …

[图书][B] Biodefense: research methodology and animal models

JR Swearengen - 2005 - taylorfrancis.com
The importance attached to rapidly developing our biodefensive capabilities has recently
resulted in a significantly increased funding for biodefense research. Accordingly …

Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor

Y Do, AM Didierlaurent, S Ryu, H Koh, CG Park, S Park… - Vaccine, 2012 - Elsevier
It is of great interest to develop a pneumonic plague vaccine that would induce combined
humoral and cellular immunity in the lung. Here we investigate a novel approach based on …

TNFα and IFNγ but Not Perforin Are Critical for CD8 T Cell-Mediated Protection against Pulmonary Yersinia pestis Infection

FM Szaba, LW Kummer, DK Duso, EP Koroleva… - PLoS …, 2014 - journals.plos.org
Septic pneumonias resulting from bacterial infections of the lung are a leading cause of
human death worldwide. Little is known about the capacity of CD8 T cell-mediated immunity …